

Enmale

1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SHINKAWA et al

Serial No. 09/970,154 ✓

Filed: October 4, 2001

For: METHOD FOR PURIFYING ANTIBODY

Atty. Ref.: 249-201

Group: Unassigned

Examiner: Unassigned

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 26, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____


B. J. Sadoff

Reg. No. 36,663

BJS:pp
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

SHINKAWA et al
Serial No. 09/970,154



Sheet 1 of 1

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

249-201

09/970,154

APPLICANT

SHINKAWA et al

(Use several sheets if necessary)

FILING DATE

GROUP

October 4, 2001

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,018,032	01/2000	Koike et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 99/10494	03/1999	WIPO				
		WO 99/54342	10/1999	WIPO				
		WO 98/58964	12/1998	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Nose, M. et al., Inhibition of processing of asparagine-linked carbohydrate chains on IgG2a by using swainsonine has no influence upon antibody effector functions in vitro, Journal of Immunology, 1990, Vol. 145, No. 3, pp. 910-914
	Dobre, M. A. et al., Isolation of a rabbit IgG fraction with cytophilic properties, Journal of Immunology Methods, 1983, Vol. 59, No. 3, pp. 339-348
	Peng, Z. et al., Binding of dog immunoglobulins G.A.M, and E to concanavalin A, Veterinary Immunology Immunopathology, 1993, Vol. 36, No. 1, pp 83-88.
	Hiki, Y. et al., Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy, J. Am. Soc. Nephrol. 1999, Vol. 10, No. 4, pp. 760-769
	Kim, H. et al. O-glycosylation in hinge region of mouse immunoglobulin G2b, Journal of Biological Chemistry, 1994, Vol. 269, No. 16, pp 12345-12350

*Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)